Observing the fact that every year various registered and authorized drugs are recalled by the public regulatory agency (in example last Ranitidine cases due by the possibility of impurity presence of a cancerogenic sustantia) it is interesting to observe the innovative production strategy of some m RNA vaccine. Also for the biotechnological drugs product the regulatory agency ask quality standard for impurity for the obviously safety implications. The biotechnological drugs, as the classic chemical drugs, due by the complex manufacturing process use raw material and industrial procedure that require. Great quality monitoring according the GMP normative rules. So it is no too strange to discuss of impurities in this new kind of products and also for the covid-19 vaccine
